Out of 50,000 posts, I’m not sure I’ve ever mentioned the sector fund XBI before, but here we are. It seems to me that this fund, representing the biotech sector, is in for some serious skidding.
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.
The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027.
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as volatility rises quickly?
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and investments.
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.
